Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 37Rituximab 31fludarabine phosphate 26Filgrastim 20ibrutinib 19Bortezomib 19fludarabine 17Peripheral Blood Stem Cell Transplantation 15Lenalidomide 15Bendamustine Hydrochloride 14Etoposide 12Cytarabine 9aldesleukin 7Vorinostat 7Tacrolimus 7Radiotherapy 7Prednisone 7Paclitaxel 7Melphalan 7Cyclosporine 7Biopsy 7venetoclax 6tanespimycin 6sargramostim 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carmustine 6Vincristine 5Specimen Handling 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Mantle-Cell × Erythromycin × Clear all
NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡